# Association of plasma endocan levels with metabolic parameters and predictive value of endocan for the development of complications in patients with type 2 diabetes mellitus: An observational study

## TL;DR

This study found that higher plasma endocan levels in type 2 diabetes patients are linked to worse metabolic control and a higher risk of diabetes-related complications.

## Contribution

The study identifies plasma endocan as a potential biomarker for predicting complications in type 2 diabetes.

## Key findings

- Plasma endocan levels are significantly higher in type 2 diabetes patients with poor metabolic control (HbA1c > 7%).
- Elevated endocan levels are strongly correlated with increased risk of complications like retinopathy, nephropathy, and myocardial infarction.
- Endocan levels show strong positive correlations with HbA1c, fasting glucose, LDL cholesterol, and triglycerides.

## Abstract

The aim of the current research was to investigate the association between plasma endocan levels and metabolic control parameters, as well as to evaluate its predictive value for clinical complications in patients with type 2 diabetes mellitus (DMT2). A total of 100 DMT2 patients participated in this prospective observational study. Plasma endocan levels were significantly elevated in DMT2 patients with HbA1c > 7% (1.38 ± 0.33 vs 0.68 ± 0.23 ng/mL; P < 0.0001), compared to patients with HbA1c ≤ 7%. Patients with plasma endocan concentrations >1.10 ng/mL (median value of 1.10 ng/mL) demonstrated significantly higher levels of metabolic parameters: body mass index (BMI), HbA1c (%), fasting glucose level, LDL cholesterol, total cholesterol, triglycerides, along with significantly lower HDL cholesterol levels. Furthermore, patients with plasma endocan levels >1.10 ng/mL were found to have an increased risk for the following complications: retinopathy (relative risk [RR]: 2.7500; 95% confidence interval [CI]: 1.2150–6.2244; P ═ 0.0152, nephropathy (RR: 2.0952; 95% CI: 1.2294–3.5710; P ═ 0.0065), neuropathy (RR: 1.9945; 95% CI: 1.2025–3.3081; P ═ 0.0075), angina pectoris (RR: 2.4881; 95% CI: 1.0865–5.6979; P
= 0.0311, hypertension (RR: 1.1372; 95% CI: 1.0060–1.2856; P
= 0.0398), cardiomyopathy (RR: 2.6190; 95% CI: 1.1507–5.9612; P
= 0.0218), myocardial infarction (RR: 9.4286; 95% CI: 1.2742–69.7697; P
= 0.0280) and stroke (RR: 4.4638; 95% CI: 1.3765–14.4758; P
= 0.0127). Correlation analysis revealed that plasma endocan levels were positively correlated with HbA1c (%) (r ═ 0.856, P < 0.0001), fasting glucose level (r ═ 0.631, P < 0.0001), LDL (r ═ 0.347, P ═ 0.0004), cholesterol (r ═ 0.282, P ═ 0.0045), and triglycerides (r ═ 0.366, P ═ 0.0002). Conversely, plasma endocan levels were negatively correlated with HDL cholesterol (r ═ −0.429, P < 0.0001). In conclusion, higher plasma endocan levels were strongly associated with poor metabolic control in DMT2 patients and exhibited significant predictive value for both microvascular and macrovascular complications.